118 related articles for article (PubMed ID: 17992189)
1. Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.
Youlyouz-Marfak I; Gachard N; Le Clorennec C; Najjar I; Baran-Marszak F; Reminieras L; May E; Bornkamm GW; Fagard R; Feuillard J
Cell Death Differ; 2008 Feb; 15(2):376-85. PubMed ID: 17992189
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
3. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy.
Galan-Moya EM; Hernandez-Losa J; Aceves Luquero CI; de la Cruz-Morcillo MA; Ramírez-Castillejo C; Callejas-Valera JL; Arriaga A; Aranburo AF; Ramón y Cajal S; Silvio Gutkind J; Sánchez-Prieto R
Int J Cancer; 2008 Jan; 122(2):289-97. PubMed ID: 17893873
[TBL] [Abstract][Full Text] [Related]
4. c-ABL tyrosine kinase modulates p53-dependent p21 induction and ensuing cell fate decision in response to DNA damage.
Udden SM; Morita-Fujimura Y; Satake M; Ikawa S
Cell Signal; 2014 Feb; 26(2):444-52. PubMed ID: 24177958
[TBL] [Abstract][Full Text] [Related]
5. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone.
Alpay K; Farshchian M; Tuomela J; Sandholm J; Aittokallio K; Siljamäki E; Kallio M; Kähäri VM; Hietanen S
PLoS One; 2014; 9(8):e105526. PubMed ID: 25148385
[TBL] [Abstract][Full Text] [Related]
8. Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells.
Goetz AW; van der Kuip H; Maya R; Oren M; Aulitzky WE
Cancer Res; 2001 Oct; 61(20):7635-41. PubMed ID: 11606405
[TBL] [Abstract][Full Text] [Related]
9. Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells.
Baran-Marszak F; Feuillard J; Najjar I; Le Clorennec C; Béchet JM; Dusanter-Fourt I; Bornkamm GW; Raphaël M; Fagard R
Blood; 2004 Oct; 104(8):2475-83. PubMed ID: 15217838
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
11. c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation.
Waning DL; Lehman JA; Batuello CN; Mayo LD
J Biol Chem; 2011 Jan; 286(1):216-22. PubMed ID: 21081495
[TBL] [Abstract][Full Text] [Related]
12. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
Podtcheko A; Ohtsuru A; Tsuda S; Namba H; Saenko V; Nakashima M; Mitsutake N; Kanda S; Kurebayashi J; Yamashita S
J Clin Endocrinol Metab; 2003 Apr; 88(4):1889-96. PubMed ID: 12679488
[TBL] [Abstract][Full Text] [Related]
13. STI571-resistant KT-1 cells are sensitive to interferon-alpha accompanied by the loss of T-cell protein tyrosine phosphatase and prolonged phosphorylation of Stat1.
Shimizu T; Miyakawa Y; Oda A; Kizaki M; Ikeda Y
Exp Hematol; 2003 Jul; 31(7):601-8. PubMed ID: 12842705
[TBL] [Abstract][Full Text] [Related]
14. Activation of STAT1 is required for interferon-alpha-mediated cell death.
Arulampalam V; Kolosenko I; Hjortsberg L; Björklund AC; Grandér D; Tamm KP
Exp Cell Res; 2011 Jan; 317(1):9-19. PubMed ID: 20937272
[TBL] [Abstract][Full Text] [Related]
15. Cellular response to alkylating agent MNNG is impaired in STAT1-deficients cells.
Ah-Koon L; Lesage D; Lemadre E; Souissi I; Fagard R; Varin-Blank N; Fabre EE; Schischmanoff O
J Cell Mol Med; 2016 Oct; 20(10):1956-65. PubMed ID: 27464833
[TBL] [Abstract][Full Text] [Related]
16. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.
Camicia R; Bachmann SB; Winkler HC; Beer M; Tinguely M; Haralambieva E; Hassa PO
J Cell Sci; 2013 May; 126(Pt 9):1969-80. PubMed ID: 23487038
[TBL] [Abstract][Full Text] [Related]
17. Resistance to fludarabine-induced apoptosis in Epstein-Barr virus infected B cells.
Fagard R; Mouas H; Dusanter-Fourt I; Devillers C; Bissières P; Martin A; Lenoir G; VanTan H; Feuillard J; Raphaël M
Oncogene; 2002 Jul; 21(29):4473-80. PubMed ID: 12085225
[TBL] [Abstract][Full Text] [Related]
18. Genetic disruption of Abl nuclear import reduces renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity.
Sridevi P; Nhiayi MK; Wang JY
Cell Death Differ; 2013 Jul; 20(7):953-62. PubMed ID: 23660976
[TBL] [Abstract][Full Text] [Related]
19. STAT1: a modulator of chemotherapy-induced apoptosis.
Thomas M; Finnegan CE; Rogers KM; Purcell JW; Trimble A; Johnston PG; Boland MP
Cancer Res; 2004 Nov; 64(22):8357-64. PubMed ID: 15548705
[TBL] [Abstract][Full Text] [Related]
20. Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network.
Kim SY; Cordeiro MH; Serna VA; Ebbert K; Butler LM; Sinha S; Mills AA; Woodruff TK; Kurita T
Cell Death Differ; 2013 Aug; 20(8):987-97. PubMed ID: 23598363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
